BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum

Executive Summary of April 14, 2026 Release

• BioMark Diagnostics selected as one of top four innovators to present at Canadian Thoracic Society (CTS) Research Forum.
• Presentation focuses on home-based, AI-enhanced blood test for early lung cancer detection in remote populations.
• Technology leverages metabolomics and machine learning to classify cancer-specific metabolic signatures.
• Strategic shift highlighted: moving from hospital-centric screening to decentralized, home-based model using self-collection kits.
• Target market identified as 1.4 million Canadians meeting high-risk eligibility criteria but facing geographic barriers.

Evaluation of News Significance

• The announcement represents industry recognition rather than a fundamental operational shift or financial milestone.
• It reinforces the "decentralized screening" strategy previously outlined in the December 2025 vision, indicating execution on prior commitments rather than new strategic pivots.
• Unlike the October 2025 German trial selection (which provided large-scale clinical validation) or September 2025 patent grants (IP protection), this event is a presentation of existing technology.
• No new revenue contracts, licensing agreements, or regulatory approvals are announced in this release.

Core Business

• BioMark Diagnostics develops liquid biopsy platforms for early cancer detection using metabolomics and AI/machine learning.
• Flagship Project: Home-based, AI-enhanced blood test designed for early lung cancer detection in remote and at-risk populations.
• Technology Stack: Metabolomic profiling combined with machine learning models to analyze small blood samples.